24 / 26
Page 67
Biochemistry & Molecular Biology Journal
ISSN: 2471-8084
Internat i ona l Conference on
Biotechnology, Biomarkers
& Systems Biology
M a r c h 0 4 - 0 5 , 2 0 1 9
Am s t e r d a m , N e t h e r l a n d s
Biotechnology, Biomarkers & Systems Biology 2019
S
ubstantiation of the potential relevance to cancer of the list of 115 proteins identified as being targeted solely by tumor
selective compounds was performed by two independent perspectives. On the one hand, all 115 proteins were scored on the
basis of recently derived oncogene probabilities (Oncoscores) and checked for currently available experimental data on the up-
and down-regulation in colon cancer samples. On the other hand, we used all drug target interaction data available from public
resources to rank order all drugs based on the number of known targets within the list of 115 proteins and check for whether
cancer was the primary indication among the top ranked. The results provide ample support for the use of the DIVISS approach to
identifying cancer-relevant targets. A cancer marker or tumor marker is a biomarker found in blood, pee, or body tissues that can
be raised by the proximity of at least one sorts of development. There are different tumor markers, each illustrative of a particular
alignment. In addition to their use in cancer medicine, biomarkers are often used throughout the cancer drug discovery process.
For instance, in the 1960s, researchers discovered the majority of patients with chronic myelogenous leukemia possessed a
particular genetic abnormality.
drsudhabanasode@yahoo.comCancer and tumor immunology
Sudha Bansode
Shankarrao Mohite College, India
Biochem Mol biol J 2019, Volume:5
DOI: 10.21767/2471-8084-C1-024